AN OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL OF ORAL 566C80 FOR THE TREATMENT OF PATIENTS WITH SEVERE PCP WHO ARE INTOLERANT AND/OR UNRESPONSIVE TO THERAPY WITH TRIMETHOPRIM/SULFAMETHOXAZOLE AND PARENTERAL PENTAMIDINE: